Lilly cuts Zepbound self-pay vial prices to $299, $399 and $449

Eli Lilly said on Dec. 1, 2025, that it is cutting the self-pay prices of Zepbound (tirzepatide) single-dose vials sold through its direct-to-consumer platform, LillyDirect ^[1]. Cash-paying patients with a valid prescription can now get the 2.5 mg starting dose for $299 a month, the 5 mg dose for $399, and all higher approved doses for $449 under the Zepbound Self Pay Journey Program ^[1].

What changed

The 2.5 mg vial dropped from $349 to $299, a $50 cut ^[1][3]. The 5 mg vial fell from $499 to $399, a $100 cut ^[1][3]. The 7.5 mg, 10 mg, 12.5 mg and 15 mg vials all went from $499 to $449 ^[1][3].

There is fine print on the higher doses. Lilly says the $449 price for 7.5 mg through 15 mg applies only on the first fill and when prescriptions are refilled within 45 days of the previous delivery ^[1]. Outside that window, the company's release lists regular monthly prices of $599 for 7.5 mg, $699 for 10 mg, $849 for 12.5 mg and $1,049 for 15 mg ^[1].

The sources disagree on those out-of-program numbers. Lilly's LillyDirect product page lists different regular prices if a prescription is not refilled within 45 days: $499 for 7.5 mg, $699 for 10 mg, $699 for 12.5 mg and $699 for 15 mg ^[4]. It is not clear from the sources which figures are current for every buyer, or when the page was last updated.

A few other details matter for the math. LillyDirect defines a month as 28 days and four single-dose vials ^[4]. Vials are self-pay only, are sold exclusively through LillyDirect, and require buying needles and syringes separately ^[4]. The program is not insurance, and eligibility and terms can be changed or ended by Lilly at any time ^[4]. Delivery is free, with pickup available, and the purchases may be HSA/FSA eligible depending on the plan ^[4].

For comparison, CNBC reports Zepbound carries a list price of roughly $1,086 per month, and that spotty insurance coverage for weight-loss drugs in the U.S. has been a major barrier ^[2]. Lilly also sells Zepbound single-dose pens, which on LillyDirect are advertised at as low as $25 a month with insurance for up to a three-month prescription, with government beneficiaries excluded ^[4].

"Far too many people who need obesity treatments still face cost and coverage barriers," said Ilya Yuffa, executive vice president and president of Lilly USA and Global Customer Capabilities, adding that the company will keep "expanding choices for delivery devices and creating new pathways for access" ^[1].

Why it matters for patients

For people paying out of pocket, this is a direct change in the monthly bill, and it takes effect now rather than after a future regulatory step ^[2]. The largest percentage savings land on the 5 mg dose, one of the approved maintenance doses for weight reduction ^[1].

The 45-day refill condition means the advertised price depends on staying on a tight refill schedule ^[1]. Someone who pauses treatment, has a shipping delay, or spaces out doses could face a much higher price on the next fill ^[1][4]. Vials also require drawing up the dose with a separate needle and syringe, an added step and cost compared with pens ^[2][4].

The move comes as cash prices across the category shift. Novo Nordisk lowered cash prices for Wegovy and Ozempic to $349 a month from $499 for existing self-pay patients, excluding the highest Ozempic dose, and added a temporary $199-a-month introductory offer for the first two months on the two lowest doses of either drug ^[2][3]. Lilly said earlier that direct-to-consumer sales now account for more than a third of new Zepbound prescriptions ^[2].

What happens next

Lilly's November agreement with the Trump administration centers on lower prices for a different form of Zepbound, a multi-dose pen, and depends on FDA approval that has not yet happened ^[1][2]. The administration's direct-to-consumer website, TrumpRx, is set to launch in January, and the deals also introduce Medicare coverage of obesity drugs for certain patients ^[2]. Lilly's stock fell nearly 2% on the day of the announcement ^[2].